线粒体编码肽 MOTS-c

MOTS-c is a peptide that your own mitochondria produce — and the fact that it's encoded in mitochondrial DNA rather than nuclear DNA makes it one of the more unusual signaling molecules in metabolic research. It's 16 amino acids long, derived from the 12S rRNA region of the mitochondrial genome, and it behaves less like a traditional hormone and more like an alarm signal your cells send when energy metabolism is under stress.^[1]

What makes it genuinely interesting is where it goes when that alarm fires. Under metabolic stress, MOTS-c translocates from the mitochondria to the cell nucleus, where it directly influences gene expression to restore metabolic homeostasis.^[2] That's a mitochondria-to-nucleus communication pathway — retrograde signaling — and it's a relatively new area of biology that researchers are still mapping out.

The research case for MOTS-c centers on metabolic disease: insulin resistance, type 2 diabetes, obesity, and age-related metabolic decline. Circulating MOTS-c levels fall with age,^[1] which has led some researchers to ask whether supplementing it could slow or reverse some of that decline. We don't have a clinical answer to that question yet — but the preclinical data is compelling enough that this peptide has attracted serious scientific attention.

• MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA — one of a small class of mitochondrial-derived peptides (MDPs) now recognized as metabolic signaling molecules.

There are no published clinical trials establishing an official human dose for MOTS-c. The ranges below reflect what has been used in animal studies and, to a limited extent, what practitioners working with this compound have reported — not data from randomized controlled trials.

Not clinical dosing data

No completed Phase 2 or Phase 3 human trials have established a safe or effective dose range for MOTS-c in humans. Animal study doses are not reliably translatable to human equivalents without clinical pharmacokinetic data. Any use outside a formal research context carries unknown risk. Discuss with a licensed healthcare provider who is familiar with the current literature.

In mouse models, doses of approximately 5 mg/kg administered intraperitoneally have been used to study metabolic effects including improvements in insulin sensitivity and reductions in diet-induced obesity.^[2] A gestational diabetes mouse model study used MOTS-c treatment to demonstrate reductions in hyperglycemia and insulin resistance, though specific dose amounts were not fully detailed in the abstract available.^[3]

Human pharmacokinetic data — half-life, bioavailability by route, volume of distribution — is not yet published in peer-reviewed literature to a degree that would support a practical dosing guide. If you're seeing specific human dose ranges circulating in practitioner communities (commonly cited as 5–10 mg per injection — MOTS-c has no established human clinical dosing; dosing ranges cited in practitioner communities lack peer-reviewed human evidence and remain unvalidated), those figures are not derived from published clinical trials and should be treated accordingly.

For anyone interested in MOTS-c research, the honest answer right now is: we don't have the human data to say what dose works, what dose is safe, or what route of administration is optimal. That's not a hedge — it's just where the science is.

Most metabolic peptides you'll read about on this site originate from nuclear DNA and act on receptors at the cell surface. MOTS-c does something fundamentally different: it's produced inside the mitochondria, and it communicates directly with the nucleus.^[1] That makes it part of a newly recognized class of signaling molecules — mitochondrial-derived peptides (MDPs) — that includes humanin and the SHLP peptides, but MOTS-c has attracted the most metabolic research attention of the group.^[4]

The other thing that sets it apart is the age-decline pattern. Your circulating MOTS-c levels don't stay constant — they fall as you get older.^[1] That's the same pattern you see with growth hormone, IGF-1, and other anabolic and metabolic signals, and it's raised the same hypothesis: could restoring youthful levels of MOTS-c slow some aspects of metabolic aging? The preclinical data suggests this is worth investigating seriously. Whether it holds up in humans is the open question.

A peptide from an unexpected address

Most therapeutic peptides are encoded in nuclear DNA. MOTS-c is encoded in the mitochondrial genome — specifically the 12S rRNA region — making it one of only a handful of known peptides with this origin. This also means its expression is regulated differently from nuclear-encoded peptides, and its biology is tied directly to mitochondrial function and stress signaling.

Start with the mitochondria. They're not just the cell's power generators — they're also active signaling hubs that communicate metabolic status to the rest of the cell. MOTS-c is one of the signals they send.^[2]

Under normal conditions, MOTS-c is produced in the mitochondria and circulates in the bloodstream. When metabolic stress hits — think high-fat diet, insulin resistance, or the kind of cellular energy imbalance that comes with aging — MOTS-c translocates into the cell nucleus, where it binds to DNA and regulates the expression of genes involved in metabolic balance.^[1] This retrograde signaling pathway (mitochondria → nucleus) is the core of what makes MOTS-c mechanistically interesting.

In skeletal muscle specifically, MOTS-c activates AMPK (AMP-activated protein kinase), which you can think of as the cell's master fuel gauge. When AMPK is activated, the cell shifts toward burning glucose and fatty acids more efficiently, and insulin sensitivity improves.^[2] Skeletal muscle is the primary site of insulin-stimulated glucose disposal in the body — it's where most of your post-meal blood sugar gets cleared — so improving its insulin sensitivity has outsized effects on whole-body glucose metabolism.

The downstream effects in animal models include reduced fat accumulation, improved glucose tolerance, and protection against diet-induced obesity.^[2] In a gestational diabetes mouse model, exogenous MOTS-c treatment reduced hyperglycemia and improved insulin resistance — effects attributed to its action on skeletal muscle glucose uptake.^[3]

There's also emerging evidence for MOTS-c in cancer biology. In ovarian cancer patients, MOTS-c levels were found to be reduced in both serum and tumor tissue, and lower levels correlated with worse prognosis. Exogenous MOTS-c inhibited ovarian cancer cell proliferation and migration in laboratory studies, with the mechanism involving suppression of a deubiquitination pathway (USP7-mediated LARS1 deubiquitination).^[5] This is early-stage research, but it opens a line of investigation beyond metabolic disease.

Here's the honest picture: the evidence base for MOTS-c is preclinical. The foundational 2015 paper in Cell Metabolism — one of the most respected journals in the field — established the core biology: MOTS-c regulates insulin sensitivity and metabolic homeostasis, with skeletal muscle as its primary target organ.^[2] That paper used mouse models and showed that MOTS-c treatment reduced diet-induced obesity and insulin resistance. It's a high-quality mechanistic study. It is not a human clinical trial.

Since then, research has expanded into gestational diabetes (mouse model),^[3] aging-related metabolic disease (review literature),^[4] and ovarian cancer (human tissue samples plus cell line studies).^[5] A 2023 review in Frontiers in Endocrinology summarized the therapeutic potential across these areas and noted that MOTS-c plasma levels decline with age — a finding with obvious implications for aging research, but one that still needs clinical translation.^[1]

What doesn't exist yet: a completed Phase 2 randomized controlled trial in humans for any indication. The clinical evidence level is genuinely preclinical, and that matters when you're trying to understand what MOTS-c can and can't be said to do in a human body.

• Human efficacy data — Every metabolic benefit described above comes from animal models or in-vitro studies. We don't have a randomized controlled trial showing that exogenous MOTS-c improves insulin sensitivity, reduces obesity, or extends healthspan in humans.
• Safe human dose range — No clinical pharmacokinetic studies have established what dose is appropriate, what route of administration is optimal, or what the therapeutic window looks like in people.
• Long-term safety — Animal studies haven't flagged major safety signals, but the absence of evidence is not evidence of absence. Long-term human safety data simply doesn't exist.
• Anti-aging effects in humans — The observation that MOTS-c declines with age is real. Whether supplementing it slows aging-related decline in humans is an untested hypothesis, not an established finding.
• Cancer treatment — The ovarian cancer data is mechanistically interesting but limited to tissue samples and cell lines.^[5] No clinical oncology trials have been completed or reported.

Human clinical safety data for MOTS-c is essentially nonexistent. No large-scale trials have characterized an adverse effect profile. What we have is animal study data and a limited number of anecdotal reports from research contexts.

From animal studies:

• No significant toxicity reported — Mouse studies at research doses have not shown major adverse effects, but rodent tolerance does not reliably predict human tolerance.^[2]
• Injection site reactions — Not formally characterized in humans; subcutaneous injection site reactions are common with peptide administration generally, but MOTS-c-specific safety data in humans is not yet available.

What we genuinely don't know:

• Immune response — Exogenous peptides can trigger immune reactions. This hasn't been characterized for MOTS-c in humans.
• Interactions with existing metabolic medications — If MOTS-c genuinely improves insulin sensitivity, combining it with insulin or insulin secretagogues could theoretically increase hypoglycemia risk. This is speculative but worth flagging.
• Long-term effects — Unknown.

If you're considering MOTS-c for any purpose, the absence of a known side effect profile is itself a risk factor, not reassurance. Talk to a provider who can monitor relevant metabolic markers.

Research use only — no legal therapeutic pathway in the US

MOTS-c is not FDA-approved for any indication. It has no approved NDA or BLA, and it does not appear on the FDA's list of bulk drug substances that may be used in compounding. This means it cannot be legally dispensed through compounding pharmacies for human therapeutic use in the United States. Access is limited to formal research contexts. If you encounter vendors marketing MOTS-c as a therapeutic product for human use, that marketing is not consistent with current FDA regulations.

The FDA's position on research-only peptides is straightforward: without an approved application or an authorized compounding pathway, there is no legal route for a US physician to prescribe MOTS-c to a patient. This distinguishes it from compounds like BPC-157 or TB-500, which occupy a gray area, and from compounded peptides like sermorelin or ipamorelin that have established compounding pathways.

The FDA has taken enforcement action against companies marketing unapproved peptide products for human use. Patients and providers should consult FDA.gov and the FDA's MedWatch program for current enforcement activity.

For researchers: MOTS-c is available from research chemical suppliers for in-vitro and animal study purposes. That's a separate regulatory context from human therapeutic use, and the distinction matters legally.

If you're a researcher working with MOTS-c in a laboratory context, sourcing quality matters for the integrity of your results. If you're a patient considering it for personal use, understand that you're operating outside any regulated framework — there's no prescription, no physician oversight built into the transaction, and no quality standard being enforced.

What to look for from a research supplier:

• Independent Certificate of Analysis (COA) — Third-party lab verification, not in-house testing. The COA should specify purity by HPLC (high-performance liquid chromatography) and confirm the amino acid sequence.
• HPLC purity ≥ 98% — Standard for research-grade peptides. Lower purity means unknown contaminants.
• Mass spectrometry confirmation — Verifies the molecular weight matches the expected sequence. For a 16-amino-acid peptide like MOTS-c, this is a meaningful quality check.
• Sterility testing — Required for any injectable use. Most research chemical suppliers do not provide sterile, injectable-grade product.

Red flags:

• No COA or "in-house testing only" — The most common marker of a low-quality supplier. Independent verification is the minimum standard.
• Price significantly below market — Peptide synthesis and third-party testing cost money. Suspiciously cheap product usually means corners were cut somewhere.
• Claims of therapeutic benefit or FDA compliance — Any supplier making these claims for MOTS-c is misrepresenting the regulatory status of the compound.

If MOTS-c interests you because of its metabolic effects, the peptides with the most clinical evidence in that space are the GLP-1 receptor agonists — semaglutide and tirzepatide — which have completed Phase 3 trials and FDA approval for weight loss and type 2 diabetes. They work through a completely different mechanism (incretin signaling rather than mitochondrial retrograde signaling), but if your goal is clinically validated metabolic improvement, those are where the evidence is.

For longevity and anti-aging research specifically, humanin is MOTS-c's closest relative — also a mitochondrial-derived peptide, also showing age-related decline, also in preclinical stages for most indications. Epithalon and BPC-157 are other peptides frequently discussed in longevity contexts, though with different mechanisms and varying evidence quality. None of them have the clinical trial depth of the approved GLP-1 drugs, and MOTS-c sits at the earlier end of the evidence spectrum even within that group.